J&J withdraws application with FDA for new ovarian cancer drug
Johnson & Johnson, the owner of rights to Yondelis in the United States, has withdrawn its New Drug Application with the Food and Drug Administration for approval of the drug to treat ovarian cancer.
The drug is being used in trials with Doxil to treat recurrent ovarian cancer. In September, 2009, the FDA requested additional data from J&J, including overall survival data. This data will be presented at the ASCO meeting in June.
Read more here